NCT04334759 2026-01-22
DREAM3R
PrECOG, LLC.
Phase 3 Completed
Clinical Trials
13 trialsNCT05380713 2025-12-29
......SMARTEST Trial......
University Health Network, Toronto
Phase 2 Completed
NCT03421353 2024-08-21
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
AstraZeneca
Phase 1 Completed
NCT02718911 2023-10-16
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT02899195 2023-07-05
PrE0505
PrECOG, LLC.
Phase 2 Completed
NCT04115111 2023-03-15
Diadem
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT03889275 2023-02-21
A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT02592551 2022-09-29
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Baylor College of Medicine
Phase 2 Completed
NCT04261075 2022-08-15
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
MedImmune LLC
Phase 1 Completed
NCT02900157 2021-01-14
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT03089645 2020-07-27
MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
MedImmune LLC
Phase 1 Completed
NCT02261220 2020-03-06
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT02141347 2018-12-12
Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma
AstraZeneca
Phase 1 Completed